Press Releases<< Back
Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test
"A liquid biopsy test has the potential to improve patient compliance during a surveillance protocol while monitoring for bladder cancer recurrence for patients with non-muscle invasive disease," said
Early-stage bladder cancer is estimated to recur in 10 to 15 percent of patients in the first year and in more than half of patients over time. Currently, bladder cancer surveillance is repeated at frequent intervals via a cystoscopy, a procedure that inserts an instrument equipped with a camera and light to look at the inside of the bladder.
By measuring multiple target tumor-specific biomarkers using
"This study represents one of many efforts in our robust research and development program to deliver multiple liquid-based tests for various tumor types beginning in 2016," said
The study, presented at the
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the value and benefits of urine-based monitoring of bladder cancer patients; the expectation that the test results could enable a urine-based test for monitoring bladder cancer recurrence in early-stage patients, and the potential benefits of such a test; and the company's belief that the study results demonstrate continued progress toward development of non-invasive tests for individualized treatment at various stages of disease. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the company's ability to develop and commercialize new tests, including tests based on liquid biopsy; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomic-health-presents-positive-proof-of-concept-data-for-bladder-cancer-liquid-biopsy-test-300099473.html
News Provided by Acquire Media